A method is described herein, comprising vaporizing a glycol material by thermal contact with a heating medium to form a vaporized glycol stream, increasing a pressure of the vaporized glycol stream to form a pressurized glycol stream, and increasing a temperature of the heating medium by thermally contacting the heating medium with the pressurized glycol stream.

A method is described herein, comprising vaporizing a glycol material by thermal contact with a heating medium to form a vaporized glycol stream, increasing a pressure of the vaporized glycol stream to form a pressurized glycol stream, and increasing a temperature of the heating medium by thermally contacting the heating medium with the pressurized glycol stream.

A process can be used for preparing sodium and potassium alkoxides. The process is characterized by two simultaneously implemented but spatially separated reactions of an alcohol ROH with NaOH, and ROH with KOH, to give sodium alkoxide and potassium alkoxide, respectively. The vapours formed in this case contain the alcohol used and water. The vapours are combined, and the resulting mixed vapour is fed to a common distillation with recovery of the alcohol.

A process can be used for preparing sodium and potassium alkoxides. The process is characterized by two simultaneously implemented but spatially separated reactions of an alcohol ROH with NaOH, and ROH with KOH, to give sodium alkoxide and potassium alkoxide, respectively. The vapours formed in this case contain the alcohol used and water. The vapours are combined, and the resulting mixed vapour is fed to a common distillation with recovery of the alcohol.

The present invention relates to oxopiperazines that mimic helix αB of the C-terminal transactivation domain of HIF1α. Also disclosed are pharmaceutical compositions containing these oxopiperazines and methods of using these oxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF1α with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation).

The present invention relates to oxopiperazines that mimic helix αB of the C-terminal transactivation domain of HIF1α. Also disclosed are pharmaceutical compositions containing these oxopiperazines and methods of using these oxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF1α with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation).

The present invention relates to oxopiperazines that mimic helix αB of the C-terminal transactivation domain of HIF1α. Also disclosed are pharmaceutical compositions containing these oxopiperazines and methods of using these oxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF1α with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation).

A product 1,3-butylene glycol, in which 2,4-dinitrophenylhydrazine derivatives of 2-(hydroxyethyl)-2,6-dimethyl-1,3-dioxane have a weight proportion of 90 ppm or less, as calculated from a sum of absorbance of peaks thereof in an HPLC analysis under specific conditions after specific sample preparation.

A product 1,3-butylene glycol, in which 2,4-dinitrophenylhydrazine derivatives of 2-(hydroxyethyl)-2,6-dimethyl-1,3-dioxane have a weight proportion of 90 ppm or less, as calculated from a sum of absorbance of peaks thereof in an HPLC analysis under specific conditions after specific sample preparation.

Certain embodiments are directed to methods of purifying methanol comprising fractionating a feed source into methanol and heavy alcohol or fusel alcohol fractions and further recovering methanol from the fusel alcohol fraction.